



FOR IMMEDIATE RELEASE

**Immgenuity Inc., Announces the Appointment of Dr. Lydie Trautmann, EngD, PhD, to its Scientific Advisory Board**

Dover, Delaware, May 22, 2023 – Immgenuity, a biotech company focused on developing innovative immunotherapies, announced today that Dr. Lydie Trautmann, EngD, PhD has joined its Scientific Advisory Board.

Dr. Trautmann is Director of Translational Research, Global Infectious Diseases Portfolio, at the Henry M Jackson Foundation (HJF) for the Advancement of Military Medicine in support of Military HIV Research Program (MHRP), Emerging Infectious Diseases Branch at Walter Reed Medical Center (EIDB), and the Diagnostics and Countermeasures Branch (DCB.) She oversees the research efforts in the current and upcoming MHRP clinical trials in Thailand. Dr. Trautmann received her M.Sc. in Cell and Molecular Biology and Doctor of Engineering degrees in 1998 from Louis Pasteur University, and her Ph.D. in Immunology at Paris V University - René Descartes in 2003. Prior to her role at HJF, she performed research for two decades in translational human immunology evaluating early treatment, HIV-associated neurocognition and immune interventions aimed at achieving HIV remission at the Vaccine and Gene Therapy Institute in Florida and at the Oregon Health and Science University as well as at MHRP. She has established a strong research agenda with high ranked publications, a large collaborative network and a vigorous funding portfolio. She also serves on several national and international review committees.

Dr. Trautmann’s lab is currently focused on HIV functional cure studies. She says understanding the complexity of acute HIV infection is key to creating a viable vaccine. She and her team are working to define the impact of treatment initiation in acute infection and the quality of the immune memory response. By researching whether the memory response is better in the extremely early, middle, or late stages of acute infection, Dr. Trautmann and her team hope to provide crucial insight into immunology which could elevate vaccine development. The lab also studies the immunology of efficacious vaccines against diseases like yellow fever, to provide insights into how to create a viable HIV vaccine.

“We are thrilled to welcome Dr. Trautmann to our Scientific Advisory Board. Her expertise in HIV Immunology, and translational research will be priceless as we continue to advance our innovative therapy for remission in HIV” said Dr. Sateesh Apte, CEO of Immgenuity.

“I am enthusiastic to join the Scientific Advisory Board of Immgenuity and contribute to the development of Immgenuity’s therapeutic platform for addressing a remission. I look forward to working with the Immgenuity team to advance their the development of their promising therapeutic vaccine for HIV”, said Dr. Lydie Trautmann.

## **About Immgenuity, Inc.**

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

## **About IMTV014**

Immgenuity's immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as "salvage therapy" in the multidrug resistant population.

Contact: Media Relations: [media@immgenuity.com](mailto:media@immgenuity.com) (302) 321-5844

## **Forward Looking Statements:**

This press release contains "forward-looking statements" within the meaning of federal securities law, including statements concerning the company's outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.